Company intelligence / Profile preview

Invectys

Ownership: Private
Development stage: Phase 1

Overview

INVAC-1 completed Phase I clinical trial showing safety and well-tolerated results, with 60% of patients with late stage IV cancers showing stabilization. IVS-3001 received FDA Fast Track designation for treatment of Renal Cell Carcinoma. The company has initiated a Phase 1/2a clinical trial for solid tumors[1][5].

Therapeutic areas: Oncology
Modalities: Therapeutic vaccinesCAR-T cell therapyImmunotherapy
Industry: Biotech

Drug pipeline

5 assets

INVAC-1

4 more assets in the full pipeline.

Request access →

Partnerships

MD Anderson Cancer Center

Beyond the preview

Go deeper on Invectys.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Invectys.

Explore the full profile